Description
ADCC-Enhanced anti-CCR5 (PRO140) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CCR5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CCR5
Full Name
C-C chemokine receptor type 5
Alternative Names
CCR5, CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22, C-C motif chemokine receptor 5
Gene ID
1234
UniProt ID
Q9UK05
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CCR5 include West Nile Virus and Diabetes Mellitus, Insulin-Dependent, 22.
Related Pathways
Its related pathways are Signaling by GPCR and AKT Siganaling Pathway.
Function
Many inflammatory cc chemokines of the receptor, including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES, then transduce signals by increasing intracellular calcium levels. May play a role in controlling the proliferation or differentiation of the granulocyte lineage. (Microbial infection) is the co-receptor of human immunodeficiency virus-1/HIV-1 (CD4 is the main receptor).
Post-translational modifications
Sulfated on at least 2 of the N-terminal tyrosines. Sulfation contributes to the efficiency of HIV-1 entry and is required for efficient binding of the chemokines, CCL3 and CCL4. O-glycosylated, but not N-glycosylated. Ser-6 appears to be the major site. Also sialylated glycans present which contribute to chemokine binding. Thr-16 and Ser-17 may also be glycosylated and, if so, with small moieties such as a T-antigen. Palmitoylation in the C-terminal is important for cell surface expression, and to a lesser extent, for HIV entry. Phosphorylation on serine residues in the C-terminal is stimulated by binding CC chemokines especially by APO-RANTES.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
PRO140
Description
The antibody targeting GPCR are implicated in a wide variety of diseases such as rheumatoid arthritis and Crohn disease, as well as metabolic disease and cancer.
Antibody Indication
Cancer
